TEVA at a glance
Teva Pharmaceutical Industries Ltd (TEVA, SEC CIK 818686) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 16, 2026 and Form 4 insider filings as recently as September 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Teva Pharmaceutical Industries Ltd (TEVA) reported revenue of $17.3 billion (up 4.3% from FY2024) and net income of $1.4 billion. Diluted EPS was $1.21.
- As of June 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Teva Pharmaceutical Industries Ltd (TEVA) shares worth $5.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Savage Brian on September 18, 2026 of 4,503 shares at $38.69 per share.
- In the last 90 days, TEVA insiders reported 0 open-market purchases ($0) and 12 open-market sales ($17.7M) on Form 4, a net sale of $17.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $17.3B
- +4.3% vs prior year
- Insiders · 90 days
- 0 buys · 12 sells
- Net −$17.7M
- 13F holders
- 36 funds
- $5.7B · +2 vs prior quarter
- Latest 10-Q
- Jul 29, 2026
- Quarterly report
SignalX for TEVA
Don't miss the next TEVA filing
- Alerts as it files. A push when TEVA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TEVA, by share count.
- Ask anything. An AI agent that reads every TEVA filing and answers with sources.
TEVA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Savage Brian | M | Sep 18, 2026 | 4,503 | $34.70 |
| Savage Brian | Sell | Sep 18, 2026 | 4,503 | $38.69 |
| Savage Brian | Sell | Sep 18, 2026 | 314 | $38.70 |
| Savage Brian | M | Sep 18, 2026 | 4,503 | $34.70 |
| Savage Brian | Sell | Sep 18, 2026 | 2,525 | $39.15 |
| MIGNONE ROBERTO | Sell | Sep 18, 2026 | 367,600 | $39.06 |
| Weiss Amir | Sell | Aug 21, 2026 | 6,945 | $37.61 |
| Weiss Amir | M | Aug 21, 2026 | 2,500 | $19.61 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $16.5B | $17.3B |
| Gross Profit | - | $8.1B | $8.9B |
| Operating Income | - | -$303.0M | $2.2B |
| Net Income | - | -$1.6B | $1.4B |
| Gross Margin | - | 48.7% | 51.8% |
| Op. Margin | - | -1.8% | 12.5% |
| Net Margin | - | -9.9% | 8.2% |
| Balance Sheet | |||
| Total Assets | $43.5B | $39.3B | $40.7B |
| Equity | $7.5B | $5.4B | $7.9B |
| ROE | - | -30.5% | 17.8% |
| Per Share | |||
| EPS | $-0.50 | $-1.45 | $1.21 |
| Cash Flow | |||
| Operating CF | $1.4B | $1.2B | $1.6B |
Source: XBRL data in Teva Pharmaceutical Industries Ltd (TEVA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TEVA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 36 | $5.69B |
| Q1 2026 | 34 | $4.93B |
| Q4 2025 | 36 | $5.17B |
| Q3 2025 | 38 | $3.27B |
| Q2 2025 | 36 | $3.35B |
| Q1 2025 | 30 | $2.79B |
| Q4 2024 | 28 | $3.52B |
| Q3 2024 | 25 | $1.38B |
- Citigroup+1.69M (+204%)
- Millennium Management+1.37M (+72%)
- Goldman Sachs Group+1.30M (+27%)
- State Street Corp+1.15M (+6%)
- T. Rowe Price Group+1.05M (+165%)
- FMR LLC (Fidelity)−2.87M (-9%)
- BlackRock−1.24M (-2%)
- Morgan Stanley−457.5K (-6%)
- Two Sigma Investments−135.5K (-37%)
- Raymond James Financial−124.1K (-7%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 263 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TEVA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TEVA SEC filings: frequently asked questions
Are TEVA insiders buying or selling?
In the last 90 days, Teva Pharmaceutical Industries Ltd (TEVA) officers, directors and 10% owners reported no open-market purchases and 12 open-market sales worth $17.7 million by 8 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TEVA stock?
As of June 30, 2026, the largest Teva Pharmaceutical Industries Ltd (TEVA) holders among the 13F filers tracked by SignalX were BlackRock ($2.2 billion), FMR LLC (Fidelity) ($1.0 billion), State Street Corp ($641.6 million), Northern Trust ($269.6 million), Morgan Stanley ($236.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TEVA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Teva Pharmaceutical Industries Ltd (TEVA) reported revenue of $17.3 billion (up 4.3% from FY2024) and net income of $1.4 billion. Diluted EPS was $1.21. The figures come from the XBRL data in the 10-K.
What are the latest TEVA SEC filings?
Teva Pharmaceutical Industries Ltd (TEVA) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 16, 2026 and a Form 4 insider filing on September 22, 2026.
What is TEVA's SEC CIK number?
Teva Pharmaceutical Industries Ltd (TEVA)'s SEC Central Index Key (CIK) is 818686. EDGAR lists every TEVA filing under that number.
Ask anything about TEVA
The research agent reads TEVA's filings, financials, insider trades and 13F holders, then answers with sources.